Semler Scientific (SMLR) announced that it has formed CardioVanta, a wholly-owned subsidiary that will comprise its future healthcare business activities focused on early detection of heart failure and cardiac arrythmia monitoring. CardioVanta will be structured as a high-margin, software-as-a-service business model. It will seek capital from outside investors to validate its long-term value and fund its relatively modest initial capital needs. The markets for early detection of heart failure and cardiac arrythmia monitoring are estimated in the multibillion-dollar range and are projected to grow substantially due to rising cardiovascular disease, technology advancements such as artificial intelligence, the aging population, and increasing adoption of wearable and remote monitoring solutions. According to the Centers for Disease Control and Prevention, heart failure affects more than six million Americans and costs the U.S. healthcare system more than $30B annually. While CardioVanta will focus on cardiac technology and care systems, Semler Scientific will continue marketing its QuantoFlo device and software for early detection of peripheral artery disease.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMLR:
- Semler Scientific Updates Bylaws for Compliance Clarity
- Semler Scientific Inc call volume above normal and directionally bullish
- Semler Scientific Appoints Joe Burnett for Bitcoin Strategy
- Semler Scientific Updates Bylaws for Governance Efficiency
- Semler Scientific Acquires 185 Bitcoin for $20 Million